ATE437233T1 - Matrix-anheftungsregionen und verfahren zu deren verwendung - Google Patents

Matrix-anheftungsregionen und verfahren zu deren verwendung

Info

Publication number
ATE437233T1
ATE437233T1 AT02726395T AT02726395T ATE437233T1 AT E437233 T1 ATE437233 T1 AT E437233T1 AT 02726395 T AT02726395 T AT 02726395T AT 02726395 T AT02726395 T AT 02726395T AT E437233 T1 ATE437233 T1 AT E437233T1
Authority
AT
Austria
Prior art keywords
matrix attachment
attachment regions
relates
mar
compositions
Prior art date
Application number
AT02726395T
Other languages
English (en)
Inventor
Nicolas Mermod
Monique Zahn-Zabal
Markus Imhof
Philippe Chatellard
Pierre-Alain Girod
Original Assignee
Selexis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexis Sa filed Critical Selexis Sa
Application granted granted Critical
Publication of ATE437233T1 publication Critical patent/ATE437233T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Local Oxidation Of Silicon (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Wire Bonding (AREA)
AT02726395T 2001-01-26 2002-01-28 Matrix-anheftungsregionen und verfahren zu deren verwendung ATE437233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26435501P 2001-01-26 2001-01-26
US28139101P 2001-04-04 2001-04-04
PCT/IB2002/002137 WO2002074969A2 (en) 2001-01-26 2002-01-28 Matrix attachment regions and methods for use thereof

Publications (1)

Publication Number Publication Date
ATE437233T1 true ATE437233T1 (de) 2009-08-15

Family

ID=26950488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726395T ATE437233T1 (de) 2001-01-26 2002-01-28 Matrix-anheftungsregionen und verfahren zu deren verwendung

Country Status (10)

Country Link
US (1) US7129062B2 (de)
EP (1) EP1395669B1 (de)
JP (1) JP4307079B2 (de)
AT (1) ATE437233T1 (de)
CA (1) CA2435972C (de)
DE (1) DE60233049D1 (de)
DK (1) DK1395669T3 (de)
ES (1) ES2330201T3 (de)
SG (1) SG141239A1 (de)
WO (1) WO2002074969A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004056986A2 (en) 2002-12-20 2004-07-08 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
JP2005031812A (ja) * 2003-07-08 2005-02-03 Toshiba Corp 画像形成装置およびその制御方法
EP2298898B1 (de) 2003-10-24 2012-12-26 Selexis S.A. Gentransfer und Expression mit hoher Effizienz in Säugerzellen mittels eines Mehrfachtransfektionsverfahrens von Matrixbindungsbereichsequenzen
JP2007510434A (ja) * 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
GB0327919D0 (en) * 2003-12-02 2004-01-07 Plant Bioscience Ltd Enhanced expression
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
JP5291341B2 (ja) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
SI1809750T1 (sl) 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US7811562B2 (en) * 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
MX2007015540A (es) * 2005-06-10 2008-03-07 Genentech Inc Mejora de la expresion de anticuerpos utilizando vectores que contienen elementos aislantes.
DE602006019486D1 (de) * 2005-08-11 2011-02-17 Centocor Ortho Biotech Inc Materialien und verfahren zur erhöhung der peptidkettenexpression
EP1996705B1 (de) 2006-03-20 2011-08-31 ChromaGenics B.V. Die expression verstärkende dna-fragmente, deren verwendung und verfahren zum finden dieser
CN101627123A (zh) * 2007-01-08 2010-01-13 米利波尔公司 消除基因扩增的高表达细胞系
EP2118270A2 (de) * 2007-01-08 2009-11-18 Millipore Corporation Zellkulturverfahren für die produktion rekombinanter proteine bei verminderter konzentration von einem oder mehreren kontaminanten
EP2142560A4 (de) 2007-03-30 2010-12-01 Abbott Lab Recombinant expression vector elements (reves) zur verbesserung der expression von rekombinanten proteinen in wirtszellen
ES2719406T3 (es) 2007-12-24 2019-07-10 Id Biomedical Corp Quebec Antígenos recombinantes del VSR
CA3112632A1 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
AP2011005739A0 (en) * 2008-10-28 2011-06-30 Avesthagen Ltd An expression vector and processes thereof.
WO2010081890A1 (en) 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
WO2010081494A1 (en) 2009-01-19 2010-07-22 King Faisal Specialist Hospital And Research Centre A method of increasing protein expression in eukaryotic cells
WO2010149745A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
EP4218799A1 (de) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
WO2011015918A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant cetuximab
WO2011015917A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant tnk-tpa (tenecteplase)
WO2011015924A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant trastuzumab
WO2011015916A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant infliximab
SG178940A1 (en) 2009-09-18 2012-04-27 Selexis Sa Products and methods for enhanced transgene expression and processing
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US20130244280A1 (en) 2010-10-08 2013-09-19 Cadila Healthcare Limited Expression vector for high level expression of recombinant proteins
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105073995A (zh) * 2013-02-01 2015-11-18 瑟莱克斯公司 增强的转基因表达和加工
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
MY199321A (en) 2013-05-30 2023-10-24 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
EP3286227A2 (de) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispezifische antigenbindende proteine
MX2018003445A (es) 2015-09-22 2018-08-01 Genentech Inc Expresion de proteinas que contienen fc.
RS66622B1 (sr) 2015-10-08 2025-04-30 Zymeworks Bc Inc Antigen-vezujući polipeptidni konstrukti koji sadrže kapa i lambda lake lance, i njihove upotrebe
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
CN115073581A (zh) 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3293263A1 (de) * 2016-09-07 2018-03-14 Steinbeis Innovation gGmbH Induzierbare genexpression durch lineare at-reiche dna-fragmente in säugetierzellen und zugehörige verfahren
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
US20230193341A1 (en) 2018-10-24 2023-06-22 Selexis Sa Expression systems, recombinant cells and uses thereof
UY38836A (es) 2019-08-13 2021-02-26 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
BR112022011949A2 (pt) 2019-12-17 2022-11-22 Amgen Inc Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
JP2023515504A (ja) 2020-02-24 2023-04-13 ノバルティス アーゲー 組み換え産生されたポリペプチドの精製
US20230293690A1 (en) * 2020-07-22 2023-09-21 Deutsches Krebsforschungszentrum 5' s/mar applications
WO2025006529A1 (en) 2023-06-27 2025-01-02 Amgen Inc. Charge pair mutations to enable correct heavy-light chain pairing

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU673859B2 (en) 1992-10-05 1996-11-28 North Carolina State University Method for increasing expression and reducing expression variability of foreign genes in plant cells
US5610053A (en) * 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5907078A (en) * 1994-12-09 1999-05-25 Greenberg; Norman M. Transgenic mouse model for prostate cancer
DE19541450C2 (de) 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
US6596514B2 (en) 1996-01-11 2003-07-22 Immunex Corporation Expression augmenting sequence elements (EASE) for eukaryotic expression systems
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
EP0914421A2 (de) * 1996-02-29 1999-05-12 Immusol, Inc. Ribozyme gegen den hepatitis c virus
WO1997046687A1 (en) 1996-06-06 1997-12-11 Novartis Ag Vectors comprising sar elements
EP1471144B1 (de) 1996-12-02 2010-06-23 Genaera Corporation Biologische Variabilität von Asthma-assoziiertem Faktor 2 AAF2 (IL-9 Rezeptor) nützlich für die Behandlung und Diagnose von atopischen Allergien wie Asthma und Asthma-ähnlichen Erkrankungen
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
AU734476B2 (en) * 1997-11-05 2001-06-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US6635806B1 (en) 1998-05-14 2003-10-21 Dekalb Genetics Corporation Methods and compositions for expression of transgenes in plants
CA2333852C (en) 1998-07-21 2007-05-29 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
EP1117815A1 (de) 1998-09-29 2001-07-25 Pioneer Hi-Bred International Inc. Mar/sar elemente, die ein durch rsyn7 reguliertes konstrukt flankieren
DE19848017A1 (de) 1998-10-17 2000-04-20 Multigene Biotech Gmbh Episomal replizierender Vektor zur Expression eines Transgens in Säugerzellen
WO2000032800A1 (en) 1998-12-01 2000-06-08 Dow Agrosciences Llc Artificial matrix attachment region for increasing expression of genes introduced in plant cells
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6207879B1 (en) 1999-05-14 2001-03-27 Dekalb Genetics Corporation Maize RS81 promoter and methods for use thereof
US6429357B1 (en) 1999-05-14 2002-08-06 Dekalb Genetics Corp. Rice actin 2 promoter and intron and methods for use thereof
US6232526B1 (en) 1999-05-14 2001-05-15 Dekalb Genetics Corp. Maize A3 promoter and methods for use thereof
US6194636B1 (en) 1999-05-14 2001-02-27 Dekalb Genetics Corp. Maize RS324 promoter and methods for use thereof
CA2374365A1 (en) 1999-05-28 2000-12-07 Sangamo Biosciences, Inc. Gene switches
US20050129669A1 (en) 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
US6972349B1 (en) 1999-11-12 2005-12-06 University Of South Carolina Control of post-transcriptional gene silencing in plants
JP3507858B2 (ja) 1999-11-19 2004-03-15 奈良先端科学技術大学院大学長 植物において外来遺伝子の発現を安定化させるｄｎａ断片、外来遺伝子を植物において安定に発現させる遺伝子導入方法、外来遺伝子を安定に発現させた形質転換植物
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
US20020127199A1 (en) 2000-02-03 2002-09-12 Tang Y. Tom Novel nucleic acids and polypeptides
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
DE10006886A1 (de) 2000-02-16 2001-08-23 Hepavec Ag Fuer Gentherapie Nichthumaner helferabhängiger Virusvektor
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US6747189B1 (en) 2000-03-21 2004-06-08 Dekalb Genetics Corporation Maize glycine rich protein promoter compositions and methods for use thereof
US6730826B2 (en) 2000-03-22 2004-05-04 University Of Kentucky Research Foundation Plant trichome gland specific promoter sequence
US20030157715A1 (en) 2000-06-26 2003-08-21 Ulrich Laemmli Modulation of chromosome function by chromatin remodeling agents
EP1294406A2 (de) 2000-06-26 2003-03-26 Universite De Geneve Modulation von chromosome-funktion durch chromatinremodellierender mitteln
CA2416877C (en) 2000-07-27 2013-03-12 Apogene Gmbh & Co. Kg Somatic cloning gene transfer for producing recombinant proteins, cells and organs
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
JP2004507250A (ja) 2000-08-30 2004-03-11 ノース・キャロライナ・ステイト・ユニヴァーシティ タンパク質含量を変化させる分子デコイを含有するトランスジェニック植物
AU9379801A (en) 2000-09-09 2002-03-22 Basf Plant Science Gmbh Modified tet-inducible system for regulation of gene expression in plants
GB0022995D0 (en) * 2000-09-20 2000-11-01 Cobra Therapeutics Ltd Polynucleotide
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
AU4155602A (en) * 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
US7151204B2 (en) 2001-01-09 2006-12-19 Monsanto Technology Llc Maize chloroplast aldolase promoter compositions and methods for use thereof
DE10109780A1 (de) 2001-02-28 2002-09-05 Cardion Ag Episomale Vektoren enthaltend Matrix-Anheftungsregionen zur zellspezifischen Genexpression
EP1365801A4 (de) 2001-03-08 2004-10-13 Nuvelo Inc Verfahren und materialien in verbindung mit fibulinartigen polypeptiden und polynucleotiden
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
US20040076954A1 (en) 2001-03-12 2004-04-22 Irm, Llc Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
NZ527937A (en) 2001-03-13 2005-03-24 Novartis Ag Stable cell lines to express high levels of lentiviral Gag/Pol proteins for generation of HIV- or BIV- based lentiviral vectors
EP1478751A4 (de) 2001-03-30 2005-10-19 Avigenics Inc Lysozym-promotor in vögeln
DE10129010A1 (de) 2001-06-13 2002-12-19 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
US20040126189A1 (en) * 2001-06-27 2004-07-01 Chowdhury Ajit K. Method for stabilizing chromium-contaminated materials
US20030032597A1 (en) 2001-07-31 2003-02-13 Sebestyen Magdolna G. Targeting nucleic acids to a cellular nucleus
US7122715B2 (en) 2001-09-20 2006-10-17 Monsanto Technology Llc In vitro method to create circular molecules for use in transformation
AU2002341795A1 (en) 2001-09-21 2003-04-01 Avigenics, Inc. Production of transgenic avians using sperm-mediated transfection
US7138278B2 (en) 2001-11-20 2006-11-21 Monsanto Technology, L.L.C. Maize cytoplasmic glutamine synthetase promoter compositions and methods for use thereof
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
CA2427190A1 (en) 2002-04-30 2003-10-30 Alberta Research Council Inc. Production of recombinant epidermal growth factor in plants
US20030224477A1 (en) 2002-05-31 2003-12-04 Heartlein Michael W. Optimized promoter constructs
EP1513929A4 (de) 2002-06-18 2006-04-19 Zymogenetics Inc Hybridvektor mit einem cytomegalovirus-enhancer und promotor des myeloproliferativen sarkom-virus
US20040016015A1 (en) 2002-07-17 2004-01-22 Nguyen Thanh-Tuyen T. High efficiency germline transformation system
US6933136B2 (en) 2002-09-20 2005-08-23 Novo Nordisk A/S Method for making recombinant proteins
CN1263860C (zh) 2002-09-30 2006-07-12 华南农业大学 多基因载体的构建方法与应用
AU2003302777A1 (en) 2002-12-05 2004-06-30 Regulome Corporation Profiled regulatory sites useful for gene control
WO2004053137A2 (en) 2002-12-11 2004-06-24 Cytos Biotechnology Ag Method for protein production
AU2002953381A0 (en) 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
EP1445320A1 (de) 2003-02-05 2004-08-11 ARTEMIS Pharmaceuticals GmbH Automatisches Gen-Targeting mittels nicht toxisischer nachweissbarer Marker
WO2004094640A1 (en) 2003-04-15 2004-11-04 University Of Georgia Research Foundation, Inc. Avian transgenesis using a chicken ovalbumin gene region
EP2395017A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
WO2005005644A1 (en) 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
CN1842601A (zh) 2003-08-27 2006-10-04 奥夫莱夫塔埃克尼公司 通过靶向抑制内源贮藏蛋白增强植物种子中异源多肽的累积
ES2354160T3 (es) 2003-10-21 2011-03-10 Merck Serono Sa Secuencia de adn mínima que actúa como un aislante de cromatina, y su uso en la expresión de proteínas.

Also Published As

Publication number Publication date
EP1395669A2 (de) 2004-03-10
SG141239A1 (en) 2008-04-28
DE60233049D1 (de) 2009-09-03
US20030087342A1 (en) 2003-05-08
EP1395669B1 (de) 2009-07-22
JP2004519246A (ja) 2004-07-02
US7129062B2 (en) 2006-10-31
CA2435972C (en) 2011-09-13
WO2002074969A3 (en) 2003-12-24
JP4307079B2 (ja) 2009-08-05
CA2435972A1 (en) 2002-09-26
ES2330201T3 (es) 2009-12-07
DK1395669T3 (da) 2009-11-16
WO2002074969A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
ATE437233T1 (de) Matrix-anheftungsregionen und verfahren zu deren verwendung
BR0209989A (pt) Plataformas baseadas em cromossomas
ATE549395T1 (de) Medium und kultur von embryonalen stammzellen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EP1546174A4 (de) Verfahren und zusammensetzungen für rna-interferenz
WO2001090345A3 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
ATE296356T1 (de) Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung
AR025683A1 (es) Composiciones de d-endotoxina de bacillus thuringiensis activas contra lepidopteros y metodos de uso
BR0112633A (pt) Método para substituir, translocar e empilhar dna em genomas eucarióticos
DK1474507T3 (da) Fremgangsmåder og materialer til produktion af organiske produkter i celler af Candida arter
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DK1137798T3 (da) Fremgangsmåde til isolering af stamceller
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
DE69839215D1 (de) Dendritische zellhybride
AU2003297244A8 (en) Methods and compositions for purification of nucleic acid from a host cell
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
PT942999E (pt) Construcao armadilha de genes para a identificacao e isolamento de genes
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
AR017368A1 (es) Un procedimiento para la insercion de adn foraneo en una celula hospedante, un vector recombinante utilizado en dicho procedimiento y el uso del mismo
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
DE60228822D1 (de) Stress-resistenz als selektierbarer marker in transgenen pflanzen
DE60323267D1 (en) Rna-bioassay
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1395669

Country of ref document: EP